Q-omics provides the consensus-scored GPR151 profile across patient tissues and cancer cell-line models. GPR151 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, GPR151 is differentially expressed in 3, with the highest sampling consensus in LUSC. Additionally, GPR151 RNA expression shows 11,033 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight CESC, LUSC, and UVM as cancer lineages where GPR151 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GPR151 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GPR151 survival associations across molecular data types. GPR151 RNA expression shows survival associations in the most cancer types (13), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GPR151 RNA expression–survival associations across cancer types. High GPR151 expression shows unfavorable associations in CESC, COAD, LUSC and PAAD, but favorable associations in BLCA and BRCA. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for GPR151 RNA expression.
This table summarizes GPR151 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for GPR151. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GPR151 shows lower tumor expression in COAD and higher tumor expression in LUSC, COAD and THCA. The LUSC box plot shows higher GPR151 RNA expression in tumor versus normal tissue (log2 FC = +0.020, t-test p = .033).
This table shows molecular features associated with GPR151 in patient tissues and cancer cell lines. In patient samples, GPR151 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, GPR151 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
